Last reviewed · How we verify
NCT06746610
Screening and Molecular Diagnosis-based Individualized Precision Management of Monogenic Diabetes
NA trial testing Genetic Screening for Monogenic Diabetes in Monogenic Diabetes in 2,000 participants. Currently enrolling.
31 July 2027
Quick facts
| Lead sponsor | Tianjin Medical University General Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 2,000 |
| Start date | 1 August 2022 |
| Primary completion | 31 July 2027 |
| Estimated completion | 31 July 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Genetic Screening for Monogenic Diabetes
Conditions studied
- Monogenic Diabetes — all drugs for Monogenic Diabetes →
Sponsor
Tianjin Medical University General Hospital
Who can join
Eligibility, any sex, with Monogenic Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to establish a registry, screening, and individualized management platform for patients with monogenic diabetes mellitus(MDM) using internet-based and mobile application software. The main questions it aims to answer are: * What are the genetic mutations causing MDM in China (genetic landscape)? * How effective and safe is the individualized, molecular-diagnosis-based management platform for MDM in improving patient outcomes? Participants will: * Register in the MDM platform via mobile app or internet-based software * Undergo genetic screening for MDM diagnosis * Participate in follow-up visits for individualized management and monitoring of blood glucose control and outcomes
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06746610
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Monogenic Diabetes
Currently open trials in the same condition.
- NCT06478121 — Understanding Beta Cell Disorders Through the Study of Rare Genotypes (ENDURE) · recruiting
- NCT07492004 — China Monogenic Diabetes Registry · recruiting
- NCT03988764 — Monogenic Diabetes Misdiagnosed as Type 1 · recruiting
Other Tianjin Medical University General Hospital trials
Trials by the same sponsor.
- NCT06228781 — Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis · NA · not yet recruiting
- NCT07498595 — TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC · EARLY_PHASE1 · not yet recruiting
- NCT07498439 — TILs Therapy for Multiple Primary Early-Stage NSCLC · EARLY_PHASE1 · not yet recruiting
- NCT07018375 — The Effect of Oliceridine Patient-Controlled Intravenous Analgesia on Postoperative Chronic Pain After Video-Assisted Th · Phase 4 · not yet recruiting
- NCT07420296 — Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06746610 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University General Hospital
- Last refreshed: 24 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06746610.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing